Christophe Antczak

机构：Novartis (Switzerland), Novartis (France), Novartis Institutes for BioMedical Research · ORCID：0000-0001-5826-5077

发表论文 79 篇 · 总被引 2033 次 · h-index 25

代表论文

• Discovery of a ZIP7 inhibitor from a Notch pathway screen (2018 · Nature Chemical Biology · 被引 72)
• Fluopack screening platform for unbiased cellular phenotype profiling (2020 · Scientific Reports · 被引 15)
• An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cells (2020 · PLoS ONE · 被引 13)
• GATA1 deletion in human pluripotent stem cells increases differentiation yield and maturity of neutrophils (2023 · iScience · 被引 12)
• Supplementary Figure 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors (2023)
• Supplementary Table 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors (2023)